Effects of valproic acid on proliferation, apoptosis, angiogenesis and metastasis of ovarian cancer in vitro and in vivo

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 8, 2012, Pages 3977-3982

  Shan, Zhao ^a   Feng Nian, Rong ^b   Jie, Geng ^c   Ting, Zhou ^b  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^c 174 Hospital of PLA   (China)

Author keywords

Apoptosis; DDP; Ovarian cancer; Valproic acid

Indexed keywords

EID: 84873682553     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.8.3977     Document Type: Article

References (27)

1. Anderson GD (2002). Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia, Suppl 3, 53-9.
2. Allfrey V G, Faulkner R., Mirsky A E, (1964). Acetylation and Methylation of Histones and Their Possible Role in the Regulation of Rna Synthesis. Proc Natl Acad Sci USA, 51, 786-94.
3. Boring C, Squires T, Tong T (1992). Cancer statistics 1992. CA Cancer J Clin, 42, 19-38.
4. Bellarosa D, Bressan A, Bigioni M, et al (2012). SAHA/ Vorinostat induces the expression of the CD137 receptor/ ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line. Int J Oncol. doi: 10.3892/ijo.2012.1551.
5. BDaud AI, Dawson J, DeConti RC, et al (2009). Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res, 7, 2479-87.
6. Blaheta R A., Michaelis M., Natsheh I, et al (2007). Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Cancer, 96, 1699-706.
7. Blaheta RA, Michaelis M, Natsheh I, et al (2007). Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Cancer, 96, 1699-706.
8. Cinatl JJ, Cinatl.J, Hernáiz Driever P, et al (1997). Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs, 8, 958-63.
9. Chou C W, Wu M S, Huang W C, et al (2011). HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PLoS One, 3, e18087.
10. Chen Y, Tsai YH, Tseng SH, (2011). Combined valproic acid and celecoxib treatment induced synergistic cytotoxicity and apoptosis in neuroblastoma cells. Anticancer Res, 6, 2231-9.
11. Dreifuss F E, Langer D H, (1988). Side effects of valproate. Am J Med, Suppl 1A, 34-41.
12. Dive C, Wyllie AH (1993). Apoptosis and cancer chemotherapy. Cancer Chemotherapy, 4, 21-56.
13. Francisco R, Pérez-Perarnau A, Cortés C, et al (2012). Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells. Cancer Lett, 1, 42-52.
14. Feng L, Pan M, Sun J, et al (2012). Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells. J Mol Med (Berl). [Epub ahead of print]
15. Glaser K B, (2007). HDAC inhibitors: Clinical update and mechanismbased potential. Biochem Pharmacol, 74, 659-71.
16. Hede K, (2006). Histone deacetylase inhibitors sit at crossroads of diet, aging, cancer. J Natl Cancer Inst, 9, 377-9.
17. Kim M S, Blake M, Baek JH, et al (2003). Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res, 63, 7291-300.
18. Leiva M, Moretti S, Soilihi H, et al (2012). Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. Leukemia, 7, 1630-7.
19. Lin CT, Lai HC, Lee HY (2008). Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci, 6, 1218-26.
20. Marks PA, Rifkind RA, Richon VM, et al (2001). Histone deacetylases and cancer: causes and therapies. Nature, 1, 194-202.
21. Morkve O, Laerum OD, (1991). Flow cytometric measurement of p53 protein expression and DNA content in paraffin-embedded tissue from bronchial carcinomas. Cytometry, 5, 438-444.
22. Osuka S, Takano S, Watanabe S, et al (2012). Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain. Neurol Med Chir (Tokyo), 4, 186-93.
23. Ogryzko VV, Hira TH, Russanova VR, et al (1996). Human fibroblasts commitment to a senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent. Mol Cell Biol, 16, 5210-8.
24. Rodriguez-Menendez V, Gilardini A, Bossi M, et al (2008). Valproate protective effects on cisplatin-induced peripheral neuropathy: an in vitro and in vivo study. Anticancer Res, 1A, 335-42.
25. Tumber A, Collins LS, Petersen K D, et al (2007). The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol, 60, 275-83.
26. Vallo S, Xi W, Hudak L, et al (2011). HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro. Anticancer Drugs, 10, 1002-9.
27. Wedel S, Hudak L, Seibel JM, et al (2011). Impact of combined HDAC and MTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clin Exp Metastasis, 5, 479-91.